EGFR and non-small cell lung carcinoma: Therefore, the treatment option of EGFR TKIs can be selected for most NSCLC patients by performing ODxTT and AmoyDx panel. In contrast, addressing the forthcoming challenge involves ensuring the identification of the remaining three cases without overlooking them in CDx tests.